Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21703985 | 0.81 | LIMK1 (0.34) | LIMK1L3MBTL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL24729646 | 0.68 | ALDH1A1 (0.45) | LIMK1KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL20731005 | 0.68 | ALDH1A1 (0.62) | LIMK1KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL21704211 | 0.67 | KDM4E (0.33) | LIMK1KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23938225 | 0.67 | ABCB1 (0.35) | LIMK1L3MBTL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23938107 | 0.66 | KDM4E (0.42) | LIMK1KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23938084 | 0.64 | IKBKB (0.43) | LIMK1L3MBTL1MAPTNOS1IKBKB | |
| SCHEMBL20731564 | 0.64 | USP25 (0.38) | — | |
| SCHEMBL23937997 | 0.63 | KDM4E (0.41) | LIMK1L3MBTL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23317016 | 0.63 | LIMK1 (0.56) | LIMK1L3MBTL1MAPTNOS1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | LIMK1 4396/4885L3MBTL1 1885/4885KDM4E 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.